海外の治験の状況「前立腺癌」での検索結果
107件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 国名
- 登録日
Not recruiting
- Caudal anaesthesia vs lignocaine gel for TRUS biopsy of the prostate. A randomised controlled trial
- Prostate cancer
- New Zealand
- 2007-01-31
Not recruiting
- A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
- Prostatic Neoplasms, Castration-Resistant
- Australia, Austria, Belgium, Canada, China, Czech Republic, Czechia, Denmark, France, Germany, Greece, Hungary, Italy, Japan, Korea, Republic of, Poland, Russian Federation, Spain, Switzerland, Taiwan, United Kingdom, United States
- 2017-01-09
Not Recruiting
- The evaluation of lenalidomide, with or without Docetaxel plus Prednisone, in the treatment of prostate cancer, when the cancer does not respond to hormonal treatment
- Chemo-naïve metastatic prostate cancer subjects with documented rising Prostate Specific Antigen (PSA) or documented Progressive Disease (PD) following hormonal therapy MedDRA version: 16.1 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Austria, Belgium, Canada, Czech Republic, Denmark, Germany, Greece, Hungary, Israel, Italy, Mexico, Netherlands, Russian Federation, South Africa, Spain, Sweden, United Kingdom, United States
- 2009-09-17
Not recruiting
- Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
- Prostate Cancer;Castration Resistant Prostate Cancer;Pain;Prostatic Neoplasms
- Australia, Austria, Belgium, Canada, France, Germany, Ireland, Italy, Netherlands, Puerto Rico, Spain, Sweden, United Kingdom, United States
- 2012-05-22
Not Recruiting
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy
- Prostatic Neoplasms;C61 - Malignant neoplasm of prostate
- Australia, Austria, Belgium, Canada, France, Germany, Hungary, Ireland, Netherlands, Spain, United Kingdom, United States
- 2013-11-05
Not Recruiting
- A Multicenter, Open-Label, Randomized, Phase III Trial Comparing Immediate Adjuvant Hormonal Therapy (ELIGARD®- Leuprolide Acetate) in Combination With TAXOTERE® (Docetaxel) Administered Every Three Weeks Versus Hormonal Therapy Alone Versus Deferred Therapy Followed by the Same Therapeutic Options in Patients With Prostate Cancer at High Risk of Relapse After Radical Prostatectomy
- Prostatic Neoplasms;C61 - Malignant neoplasm of prostate
- Australia, Austria, Brazil, Canada, France, Germany, India, Israel, Italy, Mexico, Netherlands, Poland, Russian Federation, South Africa, Turkey, United Kingdom, United States
- 2015-11-11
Not Recruiting
- Study to find out the effects and fate of treatment with Orteronel plus prednisone in Japanese and non Japanese people that have not recieved cancer therapy for prostate cancer.
- progressive castration-resistant prostate cancer. br>MedDRA version: 16.1 Level: SOC Classification code 10029104 Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps) System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Austria, Germany, Greece, Ireland, Italy, Japan, Netherlands, New Zealand, Portugal, United Kingdom, United States
- 2012-06-12
Not Recruiting
- A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100
- Prostate Cancer # Castration Resistant Prostate Cancer # Pain # Prostatic Neoplasms;C61 - Malignant neoplasm of prostate
- Australia, Austria, Belgium, Canada, France, Germany, Ireland, Italy, Netherlands, Puerto Rico, Spain, Sweden, United Kingdom, United States
- 2013-08-06
Not Recruiting
- A Phase III, Randomized Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer
- Prostatic Neoplasms;C61 - Malignant neoplasm of prostate
- Australia, Austria, Belgium, Canada, France, Germany, Greece, Ireland, Italy, Netherlands, New Zealand, Poland, South Africa, Spain, Sweden, United Kingdom, United States
- 2015-11-12
Not Recruiting
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of 10 Mg Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer
- Prostate Cancer;C61 - Malignant neoplasm of prostate
- Australia, Austria, Belgium, Canada, France, Germany, Greece, Ireland, Italy, Netherlands, New Zealand, Poland, South Africa, Spain, Sweden, Switzerland, United Kingdom, United States
- 2015-11-11